JuanJuan Yin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
JuanJuan Yin has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
- Adam G. Sowalsky
Genitourinary Malignancies Branch, National Cancer Institute, Bethesda, MD, USA
25 shared publications - William Douglas Figg
Clinical Pharmacology Program, National Cancer Institute, National Institutes of Health, Bethesda, USA
23 shared publications - Cindy H. Chau
Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
20 shared publications - Kinjal Bhadresha
National Cancer Institute
20 shared publications - Andres F. Leon
Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
19 shared publications - Benjamin C. Brim
National Cancer Institute, National Institutes of Health Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research Bethesda, MD, 20892
19 shared publications
Latest Publications
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Data from TRPM4 Expression as a Predictive Biomarker and a Mechanistic Driver of Acetalax Activity in Prostate Cancer: Preclinical Efficacy Studies
Advanced and treatment-refractory prostate cancer, including castration-resistant disease, requires new therapeutic strategies. Transient receptor potential melastatin 4 (TRPM4), a calcium-activated monovalent cation channel, regulates cell volume and promotes cancer progression. Acetalax induces oncosis-like death in TRPM4-positive triple-negative breast cancers, suggesting a TRPM4-dependent vulnerability. In this study, we investigated whether TRPM4 expression defines Acetalax sensitivity in prostate cancer. We compared Acetalax sensitivity in TRPM4-high and -low prostate cancer cell lines, including androgen-dependent (LNCaP), castration-resistant (22Rv1), and androgen-independent (PC3 and DU145) models. We evaluated TRPM4 dynamics and oncosis-associated phenotypes using Western blotting and immunofluorescence. Resistant clones were developed through continuous drug exposure. TRPM4 expression in patient samples was analyzed using prostate cancer tissue microarray and The Cancer Genome Atlas. Transcriptional changes following TRPM4 loss were examined by RNA sequencing (RNA-seq). Antitumor activity and tolerability were evaluated in TRPM4-positive patient-derived xenograft (PDX) models. TRPM4-high cells (PC3, LNCaP, and 22Rv1) underwent oncosis-like swelling and TRPM4 degradation upon Acetalax exposure, whereas TRPM4-low cell and resistant clones (DU145 and chronic exposure cells) remained insensitive and lacked TRPM4 expression. RNA-seq revealed transcriptomic remodeling associated with TRPM4 loss. TRPM4 was significantly increased in tumors compared with normal tissues and was unchanged across stages or Gleason scores. In TRPM4-positive PDX models, Acetalax (300 mg/kg) significantly suppressed tumor growth without body weight loss, indicating antitumor efficacy without overt toxicity. TRPM4 is a mechanistic driver and predictive biomarker of Acetalax response in prostate cancer, supporting TRPM4-dependent targeting and providing a rationale for the clinical development of Acetalax for TRPM4-expressing and treatment-refractory prostate cancer.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from TRPM4 Expression as a Predictive Biomarker and a Mechanistic Driver of Acetalax Activity in Prostate Cancer: Preclinical Efficacy Studies
Advanced and treatment-refractory prostate cancer, including castration-resistant disease, requires new therapeutic strategies. Transient receptor potential melastatin 4 (TRPM4), a calcium-activated monovalent cation channel, regulates cell volume and promotes cancer progression. Acetalax induces oncosis-like death in TRPM4-positive triple-negative breast cancers, suggesting a TRPM4-dependent vulnerability. In this study, we investigated whether TRPM4 expression defines Acetalax sensitivity in prostate cancer. We compared Acetalax sensitivity in TRPM4-high and -low prostate cancer cell lines, including androgen-dependent (LNCaP), castration-resistant (22Rv1), and androgen-independent (PC3 and DU145) models. We evaluated TRPM4 dynamics and oncosis-associated phenotypes using Western blotting and immunofluorescence. Resistant clones were developed through continuous drug exposure. TRPM4 expression in patient samples was analyzed using prostate cancer tissue microarray and The Cancer Genome Atlas. Transcriptional changes following TRPM4 loss were examined by RNA sequencing (RNA-seq). Antitumor activity and tolerability were evaluated in TRPM4-positive patient-derived xenograft (PDX) models. TRPM4-high cells (PC3, LNCaP, and 22Rv1) underwent oncosis-like swelling and TRPM4 degradation upon Acetalax exposure, whereas TRPM4-low cell and resistant clones (DU145 and chronic exposure cells) remained insensitive and lacked TRPM4 expression. RNA-seq revealed transcriptomic remodeling associated with TRPM4 loss. TRPM4 was significantly increased in tumors compared with normal tissues and was unchanged across stages or Gleason scores. In TRPM4-positive PDX models, Acetalax (300 mg/kg) significantly suppressed tumor growth without body weight loss, indicating antitumor efficacy without overt toxicity. TRPM4 is a mechanistic driver and predictive biomarker of Acetalax response in prostate cancer, supporting TRPM4-dependent targeting and providing a rationale for the clinical development of Acetalax for TRPM4-expressing and treatment-refractory prostate cancer.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data from TRPM4 Expression as a Predictive Biomarker and a Mechanistic Driver of Acetalax Activity in Prostate Cancer: Preclinical Efficacy Studies
This file contains supplementary figures and tables, including analyses of TRPM4 expression in TCGA and SU2C cohorts, additional characterization of Acetalax-induced morphological changes in prostate cancer cell lines, comparative analyses of prostate cancer cell lines with patient tumors, transcriptomic and pathway enrichment analyses, a conceptual model of TRPM4 regulation, and supporting correlation and gene expression data tables.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from TRPM4 Expression as a Predictive Biomarker and a Mechanistic Driver of Acetalax Activity in Prostate Cancer: Preclinical Efficacy Studies
This file contains supplementary figures and tables, including analyses of TRPM4 expression in TCGA and SU2C cohorts, additional characterization of Acetalax-induced morphological changes in prostate cancer cell lines, comparative analyses of prostate cancer cell lines with patient tumors, transcriptomic and pathway enrichment analyses, a conceptual model of TRPM4 regulation, and supporting correlation and gene expression data tables.
- 19 May 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 25  (10) , OF1-OF16
TRPM4 Expression as a Predictive Biomarker and a Mechanistic Driver of Acetalax Activity in Prostate Cancer: Preclinical Efficacy Studies
Advanced and treatment-refractory prostate cancer, including castration-resistant disease, requires new therapeutic strategies. Transient receptor potential melastatin 4 (TRPM4), a calcium-activated monovalent cation channel, regulates cell volume and promotes cancer progression. Acetalax induces oncosis-like death in TRPM4-positive triple-negative breast cancers, suggesting a TRPM4-dependent vulnerability. In this study, we investigated whether TRPM4 expression defines Acetalax sensitivity in prostate cancer. We compared Acetalax sensitivity in TRPM4-high and -low prostate cancer cell lines, including androgen-dependent (LNCaP), castration-resistant (22Rv1), and androgen-independent (PC3 and DU145) models. We evaluated TRPM4 dynamics and oncosis-associated phenotypes using Western blotting and immunofluorescence. Resistant clones were developed through continuous drug exposure. TRPM4 expression in patient samples was analyzed using prostate cancer tissue microarray and The Cancer Genome Atlas. Transcriptional changes following TRPM4 loss were examined by RNA sequencing (RNA-seq). Antitumor activity and tolerability were evaluated in TRPM4-positive patient-derived xenograft (PDX) models. TRPM4-high cells (PC3, LNCaP, and 22Rv1) underwent oncosis-like swelling and TRPM4 degradation upon Acetalax exposure, whereas TRPM4-low cell and resistant clones (DU145 and chronic exposure cells) remained insensitive and lacked TRPM4 expression. RNA-seq revealed transcriptomic remodeling associated with TRPM4 loss. TRPM4 was significantly increased in tumors compared with normal tissues and was unchanged across stages or Gleason scores. In TRPM4-positive PDX models, Acetalax (300 mg/kg) significantly suppressed tumor growth without body weight loss, indicating antitumor efficacy without overt toxicity. TRPM4 is a mechanistic driver and predictive biomarker of Acetalax response in prostate cancer, supporting TRPM4-dependent targeting and providing a rationale for the clinical development of Acetalax for TRPM4-expressing and treatment-refractory prostate cancer.
- 19 May 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 25  (10) , OF1-OF16
TRPM4 Expression as a Predictive Biomarker and a Mechanistic Driver of Acetalax Activity in Prostate Cancer: Preclinical Efficacy Studies
Advanced and treatment-refractory prostate cancer, including castration-resistant disease, requires new therapeutic strategies. Transient receptor potential melastatin 4 (TRPM4), a calcium-activated monovalent cation channel, regulates cell volume and promotes cancer progression. Acetalax induces oncosis-like death in TRPM4-positive triple-negative breast cancers, suggesting a TRPM4-dependent vulnerability. In this study, we investigated whether TRPM4 expression defines Acetalax sensitivity in prostate cancer. We compared Acetalax sensitivity in TRPM4-high and -low prostate cancer cell lines, including androgen-dependent (LNCaP), castration-resistant (22Rv1), and androgen-independent (PC3 and DU145) models. We evaluated TRPM4 dynamics and oncosis-associated phenotypes using Western blotting and immunofluorescence. Resistant clones were developed through continuous drug exposure. TRPM4 expression in patient samples was analyzed using prostate cancer tissue microarray and The Cancer Genome Atlas. Transcriptional changes following TRPM4 loss were examined by RNA sequencing (RNA-seq). Antitumor activity and tolerability were evaluated in TRPM4-positive patient-derived xenograft (PDX) models. TRPM4-high cells (PC3, LNCaP, and 22Rv1) underwent oncosis-like swelling and TRPM4 degradation upon Acetalax exposure, whereas TRPM4-low cell and resistant clones (DU145 and chronic exposure cells) remained insensitive and lacked TRPM4 expression. RNA-seq revealed transcriptomic remodeling associated with TRPM4 loss. TRPM4 was significantly increased in tumors compared with normal tissues and was unchanged across stages or Gleason scores. In TRPM4-positive PDX models, Acetalax (300 mg/kg) significantly suppressed tumor growth without body weight loss, indicating antitumor efficacy without overt toxicity. TRPM4 is a mechanistic driver and predictive biomarker of Acetalax response in prostate cancer, supporting TRPM4-dependent targeting and providing a rationale for the clinical development of Acetalax for TRPM4-expressing and treatment-refractory prostate cancer.
- Open Access
Molecular decoupling of lineage identity and morphology in aggressive variant prostate cancer
Aggressive variant prostate cancer (AVPC) is a lethal subtype of prostate cancer characterized by its androgen independence, resistance to chemotherapy, and display of neuroendocrine features which can emerge either de novo or via transformation after a prior diagnosis of adenocarcinoma. The poor clinical outcomes in patients with AVPC are associated with its profound molecular heterogeneity. In this study, we analyzed 23 consecutive AVPC cases treated at a dedicated small-cell clinic (2017-2025) using clinicogenomic and transcriptomic profiling. Transformed AVPC exhibited significantly shorter overall survival times than de novo AVPC (11.8 vs 26.0 months, P < 0.001). Integrative genomic analyses identified residual androgen signaling in subsets of cases harboring neuroendocrine lineage programs, highlighting a decoupling of lineage identity and morphology. To facilitate mechanistic and pharmacologic studies, we established NCI-LYM-1, a patient-derived organoid/PDX from an AR-negative, ASCL1+/SYP+ lymph node metastasis, which faithfully recapitulates the donor tumor's molecular and phenotypic features. Short- and long-read whole-genome sequencing combined with optical genome mapping identified biallelic inactivation of PTEN, TP53, RB1 and BRCA2 as potential drivers, demonstrating clonal concordance with circulating tumor DNA from the original patient donor. Pathway and perturbation analyses suggested that NCI-LYM-1 harbored a strong dependency on apoptotic pathways, which was confirmed by in vitro organoid testing with the BCL-2/BCL-xL inhibitor navitoclax (IC50: 0.27 ÎĽM) and the MCL-1 inhibitor AZD-5991 (IC50: 0.060 ÎĽM). Overall, NCI&-LYM-1 recapitulates the clinical aggressiveness and heterogeneity of AVPC, providing a tractable platform to identify novel precision therapies.
Open AccessMolecular decoupling of lineage identity and morphology in aggressive variant prostate cancer
Aggressive variant prostate cancer (AVPC) is a lethal subtype of prostate cancer characterized by its androgen independence, resistance to chemotherapy, and display of neuroendocrine features which can emerge either de novo or via transformation after a prior diagnosis of adenocarcinoma. The poor clinical outcomes in patients with AVPC are associated with its profound molecular heterogeneity. In this study, we analyzed 23 consecutive AVPC cases treated at a dedicated small-cell clinic (2017-2025) using clinicogenomic and transcriptomic profiling. Transformed AVPC exhibited significantly shorter overall survival times than de novo AVPC (11.8 vs 26.0 months, P < 0.001). Integrative genomic analyses identified residual androgen signaling in subsets of cases harboring neuroendocrine lineage programs, highlighting a decoupling of lineage identity and morphology. To facilitate mechanistic and pharmacologic studies, we established NCI-LYM-1, a patient-derived organoid/PDX from an AR-negative, ASCL1+/SYP+ lymph node metastasis, which faithfully recapitulates the donor tumor's molecular and phenotypic features. Short- and long-read whole-genome sequencing combined with optical genome mapping identified biallelic inactivation of PTEN, TP53, RB1 and BRCA2 as potential drivers, demonstrating clonal concordance with circulating tumor DNA from the original patient donor. Pathway and perturbation analyses suggested that NCI-LYM-1 harbored a strong dependency on apoptotic pathways, which was confirmed by in vitro organoid testing with the BCL-2/BCL-xL inhibitor navitoclax (IC50: 0.27 ÎĽM) and the MCL-1 inhibitor AZD-5991 (IC50: 0.060 ÎĽM). Overall, NCI&-LYM-1 recapitulates the clinical aggressiveness and heterogeneity of AVPC, providing a tractable platform to identify novel precision therapies.
- Open Access
- 21 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models
Figure S4 shows protein level changes after 24 hours of treatment with DMSO, A-1331852, S63845, or the combination of A-1331852 and S63845.
- 21 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models
Figure S4 shows protein level changes after 24 hours of treatment with DMSO, A-1331852, S63845, or the combination of A-1331852 and S63845.
- Open Access
- 21 August 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models
Co-targeting Mcl-1 and Bcl-xL enhances the inhibitory effect on cell viability. The effect on cell viability of A-1331852 (targeting Bcl-xL) in combination with S63845 (targeting Mcl-1; A–C) and navitoclax (targeting Bcl-xL and Bcl-2) in combination with S63845 (D–F). Cell viability was determined following either 48-hour (22Rv1 and LNCaP-95) or 72-hour treatment (VCaP-CR) by CellTiter-Glo luminescent assay. The data provided represent the mean ± SD from three independent experiments with at least three technical replicates per experiment.
- 21 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models
Co-targeting Mcl-1 and Bcl-xL enhances the inhibitory effect on cell viability. The effect on cell viability of A-1331852 (targeting Bcl-xL) in combination with S63845 (targeting Mcl-1; A–C) and navitoclax (targeting Bcl-xL and Bcl-2) in combination with S63845 (D–F). Cell viability was determined following either 48-hour (22Rv1 and LNCaP-95) or 72-hour treatment (VCaP-CR) by CellTiter-Glo luminescent assay. The data provided represent the mean ± SD from three independent experiments with at least three technical replicates per experiment.
- Open Access
- 21 August 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models
Table S2 compares the IC50 values of BH3 mimetics as single agents across 2D culture and 3D spheroids.
- 21 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models
Table S2 compares the IC50 values of BH3 mimetics as single agents across 2D culture and 3D spheroids.
- Open Access
- 21 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models
Figure S6 shows the effect of treamtent of 3D spheroids with BH3 mimetics as single agents or in combination.
- 21 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models
Figure S6 shows the effect of treamtent of 3D spheroids with BH3 mimetics as single agents or in combination.
- Open Access
- 21 August 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models
Table S1 depicts the IC50 values of BH3 mimetics as single agents in 2D models.
- 21 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models
Table S1 depicts the IC50 values of BH3 mimetics as single agents in 2D models.
- Open Access
- 21 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models
Figure S2 shows the single agent activity of BH3 mimetics across LNCaP95, VCaP-CR, and 22Rv1 cells.
- 21 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models
Figure S2 shows the single agent activity of BH3 mimetics across LNCaP95, VCaP-CR, and 22Rv1 cells.